An observational multicenter study of doravirine/lamivudine/tenofovir disoproxil fumarate (DOR/3TC/TDF) in real life in controlled HIV-infected patients
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Doravirine/lamivudine/tenofovir disoproxil fumarate (Primary)
- Indications HIV-1 infections
- Focus Therapeutic Use
Most Recent Events
- 26 Oct 2022 Results presented at the 16th International Congress on Drug Therapy and HIV Infection.
- 08 Sep 2022 New trial record
- 02 Aug 2022 Results presented at the 24th International AIDS Conference